Novo Nordisk

Novo Nordisk A/S is a global healthcare company, which engages in the the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care, and Biopharm segments. The Diabetes and Obesity Care segment includes insulin, GLP-1 and related delivery systems, oral antidiabetic products (OAD), obesity, and other serious chronic diseases. The Biopharm segment focuses on rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company was founded by Harald Pedersen and Thorvald Pedersen in 1925 is headquartered in Bagsværd, Denmark.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Novo Nordisk A/S is a global healthcare company, which engages in the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care, and Rare Disease segments. The Diabetes and Obesity Care segment includes diabetes, obesity, cardiovascular, and emerging therapy areas. The Rare Disease segment refers to rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company was founded by Harald Pedersen and Thorvald Pedersen in 1923 is headquartered in Bagsværd, Denmark.

The U.S. Senate health panel said on Tuesday it would vote later this month on whether to subpoena Novo Nordisk over the high U.S. prices for weight loss drugs Ozempic and Wegovy compared to those offered in other countries.

US Senate panel to weigh Novo Nordisk subpoena over Ozempic, Wegovy prices

ASML Hld

AstraZeneca

LVMH Moet Hennessy Louis Vuitton

SAP SE

Five mega companies may offer higher earnings and return potential with lower risk. Two Leaderboard stocks make this list.

Meet The International Megacaps That 'Match Or Surpass' Magnificent Seven Stocks

Chevron

Coca-Cola

Microsoft

Target

Taiwan Semiconductor Manufacturing

With so many moving parts in the market, investors shouldn't just focus on explosive growth ideas. Instead, they should turn to the safety of, well, safe stocks to buy.

The Safety Net Seven: 7 Stocks to Own for Unshakeable Returns

Novo Nordisk has two hugely successful assets in Ozempic and Wegovy. A recent trial also found semaglutide effective for treating chronic kidney disease.

Here's Why Demand for Ozempic and Wegovy Could Soar Even Higher

Siemens AG

Historic ECB rate cut bolstered European stocks, which calls for keeping a tab on Siemens (SIEGY), ASML Holding (ASML) and Novo Nordisk (NVO) for solid growth.

ECB Rate Cut Propels European Markets: 3 Must-Watch Stocks

GlaxoSmithKline

Pharma stocks have two unique characteristics that can make them great investments for many individuals. First, unlike the vast majority of equities, undervalued pharma stocks can rally even when the economy is performing miserably.

The 3 Most Undervalued Pharma Stocks to Buy in June 2024

Last year, Novo Nordisk, the Danish pharmaceutical giant, witnessed a significant surge in the sales of its diabetes drug Ozempic in China, doubling its revenue to almost $700 million. This remarkable growth accounts for 5 percent of Ozempic's global sales, underscoring China's pivotal role in the drug's international market.

Novo Nordisk's Ozempic sales double to $700 M in China, driven by weight-loss demand

Novo Nordisk is working hard to expand Ozempic's addressable market. The drug is helpful in treating chronic kidney disease, per a new trial.

Ozempic Just Got Even More Bullish For Novo Nordisk Stock, Yet Again

European stocks opened higher Thursday, with markets anticipating the ECB will cut borrowing costs for the first time since September 2019.

European stocks open higher as markets anticipate first ECB rate cut since 2019; Novo Nordisk up 3.5%

At least 11 generic versions of Novo Nordisk's popular diabetes drug Ozempic are in the final stages of clinical trials in China, as developers seek to profit from an early patent expiry of the therapy's active ingredient semaglutide in China.

Chinese drugmakers developing generic drugs of Novo Nordisk's Ozempic

Novo Nordisk is facing the prospect of intensifying competition in the promising Chinese market where drugmakers are developing at least 15 generic versions of its diabetes drug Ozempic and weight loss treatment Wegovy, clinical trial records showed.

Focus: Novo Nordisk braces for generic challenge to Ozempic, Wegovy in China

AbbVie

Moderna

The biotech sector has been through a lot in the past five years and it is finally rebounding. One of the most important sectors globally, it is hard to imagine life without biotech companies that provide life-changing drugs.

Biotech Blockbusters: 3 Pharma Stocks to Buy in June for Breakthrough Potential

Novo Nordisk is in a buy zone after a 39% gain year to date. The anti-obesity drug market is expect to grow to $4.4 billion by 2032.

Obesity Drug Leader In Buy Zone After Huge Gains

Netflix

Netflix and Novo Nordisk are just two names on this smorgasbord of stocks setting up or soaring past new buy points.

Netflix, Novo Nordisk Join 3 Fashionable Breakouts; 4 IPOs In Focus

A couple of new scientific studies on Ozempic were just published. Both indicate that the medicine could be useful in treating addiction.

Here Are 3 More Reasons to Be Bullish on Ozempic and Novo Nordisk Stock

Advanced Micro Devices

Eli Lilly

NVIDIA

As Nvidia stock takes aim at another record high and market-cap dominance, AMD and TSM set up alongside two top drugmakers.

Beyond The Nvidia Juggernaut: 2 Chip Giants, 2 Drugmakers In Spotlight

Designed to celebrate diverse, unique portrayals of individuals who partner with their healthcare professional to change the course of their weight-management journey, while educating on the clinical data of Wegovy® Reflects the power of personal journeys to address stigma, and the importance of us all working together to address excess weight and treat obesity PLAINSBORO, N.J. , June 3, 2024 /PRNewswire/ -- Novo Nordisk today launched The Power of Wegovy®, a new national campaign.

Novo Nordisk launches national Wegovy® campaign, Power of Wegovy®

Bristol-Myers

Enbridge

Enterprise Products Partners

Energy Transfer LP Unit

Kinder Morgan

National Retail Properties

Realty Income Corp

Pfizer

Prologis

Rexford Industrial Realty

W. P. Carey

Exxon Mobil

Amazon CEO Andy Jassy highlights key traits for success in a career professional, including working hard, being can-do, and following through on commitments. There are different paths to success, and income investors can potentially achieve a high level of success by buying quality undervalued companies that pay dividends. In this article, I highlight high-yielding names in REITs, Energy, and Healthcare that I find attractive at present.

Earn An 'Embarrassing' Amount Of Cash Flow From These Contrarian Picks

Eli Lilly and Novo Nordisk are leaders in fast-growing therapeutic areas. Both companies have excellent track records of innovations and solid results.

Prediction: These Could Be the Best-Performing Pharmaceutical Stocks Through 2030

The vast majority of patients using GLP-1 agonists such as Ozempic and Wegovy are being treated for diabetes or chronic weight management. GLP-1 medications are believed to have further applications, and Wegovy just gained FDA approval to treat people with heart disease.

Ozempic and Wegovy Are Fueling Novo Nordisk's Business, but Something Else May Be an Even Bigger Growth Driver in the Long Run

Eli Lilly and Novo Nordisk have generated incredible returns for investors in the past few years. The surging popularity of their weight loss treatments has produced a lot of bullishness.

This Is the Biggest Risk for Eli Lilly and Novo Nordisk Investors

Intuitive Surgical

Universal Health Services

Vertex Pharmaceuticals

Eli Lilly is in a buy zone, while weight-loss drug rival Novo Nordisk just forged a lower entry.

S&P 500 Giants Lead Five Healthy Stocks Near Buy Points

Novo Nordisk stock traded close to a buy point Friday afternoon as shares bounced from their 21-day line this week.

Ozempic Maker Novo Nordisk Stock Up More Than 31% In 2024, But Is It Too Late To Buy Shares?

Goldman Sachs predicts that the global market for obesity treatments will surge to $130 billion by 2030, up from an earlier estimate of $100 billion. This revised forecast reflects the growing demand for anti-obesity medications, particularly those based on GLP-1 receptor agonists, which mimic a hormone that helps regulate appetite and blood sugar levels.

Fat profits from obesity? Goldman Sachs forecasts weight loss market will hit $130bn by 2030

Novo Nordisk has filed nine lawsuits against medical spas, wellness clinics and pharmacies for allegedly selling impure products claiming to contain semaglutide, the active ingredient in its weight loss and diabetes drugs Wegovy and Ozempic, the latest legal dispute between the Danish drugmaker and companies that claim to sell semaglutide.

Ozempic-Maker Novo Nordisk Sues Pharmacies And Weight Loss Clinics For Allegedly Selling Impure Drugs

News for Novo Nordisk Stock (NVO)